|Study Participants||Healthcare Professionals||Researchers||Locations||Publications||What is TrialNet?||News and Events||Get Screened!||Home|
Information for Researchers
TrialNet recognizes the importance of ancillary studies in the overall mission to better understand the Pathway to Prevention (Natural History) of type 1 diabetes, to devise means to prolong the honeymoon phase in subjects with new onset disease, and to prevent diabetes altogether. Ancillary studies that complement the objectives and thereby enhance the value of TrialNet studies are strongly encouraged.
Ancillary studies must be reviewed and approved by TrialNet prior to initiation. Proposals will be evaluated with careful consideration for their potential impact on the objectives and performance of TrialNet studies. Further, ancillary studies must not interfere with the continued interest and participation of the study subjects and investigators. All approved studies will be reviewed yearly to evaluate their progress and impact on TrialNet as a whole.
TrialNet welcomes the submission of ancillary studies as an adjunct to ongoing protocols. A minimum of 4 weeks is required for review. Please refer to the ancillary study policies for application requirements and a description of the review process.
Current Funding Opportunities
Other Biorepository Links:
TN-01 Pathway to Prevention (Natural History)
TN-05 Anti-CD20 (Retuximab)
TN-08 GAD New Onset
TN-09 CTLA-4 Ig (Abatacept)
TN-14 Anti-IL1 Beta (Canakinumab)